Cardiovascular disease is the most common cause of mortality in patients with chronic kidney disease on hemodialysis. In addition to a high prevalence of traditional cardiovascular risk factors, other specific factors, including uremia and chronic inflammation, seem to contribute to the excess cardiovascular mortality. The findings of Serrano et al. point to a link between IgA antibodies against β2 glycoprotein I and cardiovascular events in renal dialysis patients
Atherosclerotic cardiovascular disease (CVD) is a significant cause of morbidity and mortality in pa...
Introduction: Proteomic profiling of end-stage renal disease (ESRD) patients could lead to improved ...
Autoantibodies to apolipoprotein/A-1 (anti-ApoA-1 IgG) have pro-atherogenic properties in patients a...
Cardiovascular complications are the most important cause of death in patients on dialysis with end-...
Cardiovascular disease is the most common cause of mortality in patients with chronic kidney disease...
IgA nephropathy is attributable to mesangial IgA immune complex deposition. The pathogenic potential...
INTRODUCTION: Proteomic profiling of end-stage renal disease (ESRD) patients could lead to improved ...
Background: Zinc-alpha 2-glycoprotein (ZAG) is a lipid mobilizing factor. Its anti-inflammatory acti...
Background: Cardiovascular disease is a major cause ofmorbidity and mortality in hemodialysis patien...
The association of dyslipidermia and inflammatory markers with decreased renal function has been rep...
AIM: The prevalence of anticardiolipin antibodies (ACA) is elevated amongst hemodialysis patients as...
Autoantibodies to apolipoprotein/A-1 (anti-ApoA-1 IgG) have pro-atherogenic properties in patients a...
BACKGROUND AND OBJECTIVES: Hemodialysis patients with type 2 diabetes exhibit an excessive cardiovas...
End-stage kidney disease increases mortality and the risk of cardiovascular (CV) disease. It is cruc...
Background and aims: Previous proteomics efforts in patients with chronic kidney disease (CKD) have ...
Atherosclerotic cardiovascular disease (CVD) is a significant cause of morbidity and mortality in pa...
Introduction: Proteomic profiling of end-stage renal disease (ESRD) patients could lead to improved ...
Autoantibodies to apolipoprotein/A-1 (anti-ApoA-1 IgG) have pro-atherogenic properties in patients a...
Cardiovascular complications are the most important cause of death in patients on dialysis with end-...
Cardiovascular disease is the most common cause of mortality in patients with chronic kidney disease...
IgA nephropathy is attributable to mesangial IgA immune complex deposition. The pathogenic potential...
INTRODUCTION: Proteomic profiling of end-stage renal disease (ESRD) patients could lead to improved ...
Background: Zinc-alpha 2-glycoprotein (ZAG) is a lipid mobilizing factor. Its anti-inflammatory acti...
Background: Cardiovascular disease is a major cause ofmorbidity and mortality in hemodialysis patien...
The association of dyslipidermia and inflammatory markers with decreased renal function has been rep...
AIM: The prevalence of anticardiolipin antibodies (ACA) is elevated amongst hemodialysis patients as...
Autoantibodies to apolipoprotein/A-1 (anti-ApoA-1 IgG) have pro-atherogenic properties in patients a...
BACKGROUND AND OBJECTIVES: Hemodialysis patients with type 2 diabetes exhibit an excessive cardiovas...
End-stage kidney disease increases mortality and the risk of cardiovascular (CV) disease. It is cruc...
Background and aims: Previous proteomics efforts in patients with chronic kidney disease (CKD) have ...
Atherosclerotic cardiovascular disease (CVD) is a significant cause of morbidity and mortality in pa...
Introduction: Proteomic profiling of end-stage renal disease (ESRD) patients could lead to improved ...
Autoantibodies to apolipoprotein/A-1 (anti-ApoA-1 IgG) have pro-atherogenic properties in patients a...